NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Biotechnology

Healthcare
$19.74 +0.39%

+$0.12 today

Market cap
$2.37B
Beta
0.08
P/E (TTM)
-17.2
EPS (TTM)
-$1.76
52W Low $17.63High $42.21

Volume 1.80M

Average 1.21M

NAMS Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue declines year over year

Q2 FY2026 revenue of $3.7M fell 80.7% year over year, ahead of the -88.9% change in trailing-twelve-month revenue. Sequentially, it rose 21.7% from the prior quarter. Over 3 fiscal years it compounded at -39.7% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 10 analysts of $40M (+77.7%) for the fiscal year ending Dec 2026, a step up from the -50.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.7M+21.7% QoQ
Last fiscal yearDec 2025
$22.5M-50.6% YoY
LTMJun 2026
$7.12M-88.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-80.7%+2434.5%+2515.2 pp
1 year-50.6%+77.7%+128.4 pp
3-year CAGR-39.7%+135.1%+174.8 pp
5-year CAGR+116.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
22.5M USD
Year-over-year change
-50.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How NAMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -88.9% is the lowest of 6, against a peer median of +149.0%.
  • Over three fiscal years its annual growth of -39.7% compares with a peer median of +2.0%.
NAMS Competitors
Revenue for NAMS and competitors
Company Period LTM YoY 3-year CAGR
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$1.28B USD+149.0%—
SEPNSepterna, Inc.LTM Sep 2026$96.27M USD+336.7%—
BIOABioAge Labs, Inc.LTM Mar 2026$10.32M USD+611.0%—
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$7.12M USD-88.9%-39.7%
ATHEAlterity Therapeutics LimitedFY2025A$5.44M AUD+35.3%+2.0%
DNLIDenali Therapeutics Inc.LTM Jun 2026$3.6M USD——
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$0 USD+100.0%—
VKTXViking Therapeutics, Inc.LTM Jun 2026$0 USD——
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$0 USD——
Peer median (excluding NAMS) —+149.0%+2.0%

Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0102.69M14.09M45.56M22.5M
Cost of Revenue000059K
Gross Profit0102.69M14.09M45.56M22.44M
Gross Margin—100.0%100.0%100.0%99.7%
Research & Development28.97M86.74M159.42M151.41M141.83M
Selling, General & Admin5.68M19.51M37.63M70.45M106.3M
Operating Expenses34.98M106.25M197.06M221.85M248.13M
Depreciation & Amortization5K9K49K113K220K
EBITDA(41.37M)(22.34M)(176.86M)(241.49M)(242.33M)
EBITDA Margin—-21.8%-1255.2%-530.0%-1076.9%
Operating Income(34.98M)(3.56M)(182.97M)(176.29M)(225.68M)
Operating Margin—-3.5%-1298.6%-386.9%-1002.9%
Interest Income0010.22M16.88M27.59M
Interest Expense411K287K6.8M00
Other Income / Expenses(6.81M)(19.08M)6.06M(65.31M)21.86M
Income Before Tax(41.79M)(22.63M)(176.91M)(241.6M)(203.82M)
Pre-Tax Margin—-22.0%-1255.6%-530.3%-905.7%
Income Tax Expense0027K(1K)0
Net Income(41.79M)(22.63M)(176.94M)(241.6M)(203.82M)
Net Margin—-22.0%-1255.8%-530.3%-905.7%
EPS (Basic)(3.34)(1.19)(2.15)(2.56)(1.75)
EPS (Diluted)(3.34)(1.19)(2.15)(2.56)(1.75)
Weighted Avg Shares17.75M18.97M82.16M94.36M114.4M
Weighted Avg Shares (Diluted)17.75M18.97M82.16M94.36M114.4M

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Intrinsic Alpha fair value

Locked

Current Price

$19.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.